Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Qendri · SciRah

Researcher profile · Semantic Scholar

V. Qendri

Share profile

V. Qendri — researcher profile on SciRah

h-index: 10
Works: 18
Citations: 225

Most-cited papers

Disease burden of human papillomavirus infection in the Netherlands, 1989–2014: the gap between females and males is diminishing
S. McDonald, V. Qendri, J. Berkhof, H. E. Melker +1 more
2017Cancer Causes and Control35 citations
Semantic Scholar
Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands
V. Qendri, J. Bogaards, J. Berkhof
2017Journal of Infectious Diseases30 citations Open access
Semantic Scholar
Pricing of HPV vaccines in European tender-based settings
V. Qendri, J. Bogaards, J. Berkhof
2018European Journal of Health Economics27 citations Open access
Semantic Scholar
The National Immunisation Programme in the Netherlands : Surveillance and developments in 2016-2017
R. Van Alebeek, K. Benschop, B. V. van Benthem, R. van Brinnendijk +62 more
201727 citations
Semantic Scholar
The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.
V. Qendri, J. Bogaards, I. Baussano, F. Lazzarato +2 more
2020Lancet Public Health21 citations Open access
Semantic Scholar
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
A. Chatterjee, S. Shapouri, B. Manzoor, A. Ravelo +4 more
2021Journal of Managed Care & Specialty Pharmacy18 citations Open access
Semantic Scholar
Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention
V. Qendri, T. M. Schurink-Van 't Klooster, J. Bogaards, J. Berkhof
2018Expert Review of Vaccines16 citations
Semantic Scholar
Who Will Benefit From Expanding HPV Vaccination Programs to Boys?
V. Qendri, J. Bogaards, J. Berkhof
2018JNCI Cancer Spectrum13 citations Open access
Semantic Scholar
The National Immunisation Programme in the Netherlands : Surveillance and developments in 2017-2018
D. Abraham, S. Baboe-Kalpoe, K. Benschop, B. V. van Benthem +70 more
201812 citations
Semantic Scholar
Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
Henri B. Wolff, V. Qendri, Natalia R. Kunst, F. Alarid-Escudero +1 more
2022Medical decision making10 citations Open access
Semantic Scholar
Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland
A. Deb, P. Guggisberg, T. Mutschler, K. Owusu-Edusei +5 more
2022Expert Review of Vaccines8 citations Open access
Semantic Scholar
Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies – the example of the Netherlands
Isaac Corro Ramos, V. Qendri, M. Al
2024BMC Medical Research Methodology4 citations Open access
Semantic Scholar
Disease burden of human papillomavirus infection in the Netherlands, 1989–2014: the gap between females and males is diminishing
S. McDonald, V. Qendri, J. Berkhof, H. de Melker +1 more
2017Cancer Causes and Control3 citations
Semantic Scholar
PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)
V. Qendri, J. May, B. Malcolm, F. Ejzykowicz +3 more
20201 citations Open access
Semantic Scholar
NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties
V. Qendri, M. Al, Annemieke van Dongen-Leunis, E. Krijkamp +7 more
2026PharmacoEconomics (Auckland)0 citations Open access
Semantic Scholar
EE314 Cost-Utility of Protocoled Practice Nurse-Led Care for Children With Asthma in Primary Care
V. Qendri, L. Goossens
2025Value in Health0 citations
Semantic Scholar
Statistical methods used to represent the clinical effectiveness of IO therapies based on trial data (Embase).
I. C. Ramos, V. Qendri, M. Al
2023searchRxiv0 citations
Semantic Scholar
POSA35 Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up Data from CheckMate 214
V. Qendri, J. May, F. Ejzykowicz, M. Kurt +2 more
2022Value in Health0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Bogaards×8
Invite
J. Bogaards — researcher profile on SciRah
J. Berkhof×6
Invite
J. Berkhof — researcher profile on SciRah
S. McDonald×3
Invite
S. McDonald — researcher profile on SciRah
H. de Melker×3
Invite
H. de Melker — researcher profile on SciRah

T. M. Schurink-van 't Klooster

×3

Invite

K. Benschop — researcher profile on SciRah

B. V. van Benthem×2

Invite

B. V. van Benthem — researcher profile on SciRah

Invite

I. Brinkman — researcher profile on SciRah

P. Bruijning-Verhagen×2

Invite

P. Bruijning-Verhagen — researcher profile on SciRah

C. V. van Els×2

Invite

C. V. van Els — researcher profile on SciRah

A. van der Ende×2

Invite

A. van der Ende — researcher profile on SciRah

Invite

I. Friesema — researcher profile on SciRah